Literature DB >> 25540981

Lack of Day/Night variation in fibroblast growth factor 21 levels in young healthy men.

J-P Foo1, K N Aronis2, J P Chamberland3, C S Mantzoros3.   

Abstract

BACKGROUND: Fibroblast growth factor (FGF) 21 is an endocrine factor with an emerging role as a metabolic regulator. We previously reported the presence of a significant day/night variation of FGF-21 in energy-replete, healthy female subjects. However the day/night patterns of secretion in male subjects remain to be fully elucidated. To elucidate day/night pattern of FGF-21 levels in male subjects in the energy-replete state, its relationship to FFA and to investigate whether a sexual dimorphism exists in FGF-21 physiology.
METHODS: Eight healthy lean male subjects were studied for up to 5 days while on an isocaloric diet. Blood samples were obtained for measurement of FGF-21 and free fatty acids (FFA) hourly from 0800 AM on day 4 till 0800AM on day 5.
RESULTS: FGF-21 did not exhibit any statistically significant day/night variation pattern of circulating FGF-21 levels during the isocaloric fed state in male subjects. FGF-21 levels in male subjects are closely cross-correlated with FFA levels, similar to female subjects.
CONCLUSIONS: A sexual dimorphism exists in FGF-21 physiology; that as opposed to female subjects, no significant day/night variation exists in FGF-21 rhythm in male subjects in the energy-replete state. Circulating pattern of FGF-21, similar to the female subjects, was highly cross-correlated to the FFA levels in the male subjects, signifying that the sexual dimorphism in FGF-21 physiology may be related to the differing lipid metabolism in both the genders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25540981     DOI: 10.1038/ijo.2014.215

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  28 in total

1.  Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans.

Authors:  Jean L Chan; Joseph E Mietus; Patricia M Raciti; Ary L Goldberger; Christos S Mantzoros
Journal:  Clin Endocrinol (Oxf)       Date:  2007-01       Impact factor: 3.478

2.  Nonoxidative free fatty acid disposal is greater in young women than men.

Authors:  Christina Koutsari; Rita Basu; Robert A Rizza; K Sreekumaran Nair; Sundeep Khosla; Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2010-12-01       Impact factor: 5.958

Review 3.  Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones.

Authors:  Xuewen Wang; Faidon Magkos; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2011-04       Impact factor: 5.958

4.  Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.

Authors:  Ffolliott M Fisher; Patricia C Chui; Patrick J Antonellis; Holly A Bina; Alexei Kharitonenkov; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Diabetes       Date:  2010-08-03       Impact factor: 9.461

5.  Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis.

Authors:  G Schlierf; E Dorow
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

6.  The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

Authors:  Cecilia Gälman; Tomas Lundåsen; Alexei Kharitonenkov; Holly A Bina; Mats Eriksson; Ingiäld Hafström; Maria Dahlin; Per Amark; Bo Angelin; Mats Rudling
Journal:  Cell Metab       Date:  2008-08       Impact factor: 27.287

7.  Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.

Authors:  Jie Huang; Tetsuya Ishino; Gang Chen; Paul Rolzin; Trina F Osothprarop; Kelsey Retting; Lingna Li; Ping Jin; Marla J Matin; Bernard Huyghe; Saswata Talukdar; Curt W Bradshaw; Moorthy Palanki; Bernard N Violand; Gary Woodnutt; Rodney W Lappe; Kathleen Ogilvie; Nancy Levin
Journal:  J Pharmacol Exp Ther       Date:  2013-05-29       Impact factor: 4.030

Review 8.  Role of melatonin in metabolic regulation.

Authors:  Ahmet Korkmaz; Turgut Topal; Dun-Xian Tan; Russel J Reiter
Journal:  Rev Endocr Metab Disord       Date:  2009-12       Impact factor: 6.514

9.  Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.

Authors:  Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu
Journal:  Diabetes       Date:  2008-02-05       Impact factor: 9.461

10.  Fibroblast growth factor 21 levels in young healthy females display day and night variations and are increased in response to short-term energy deprivation through a leptin-independent pathway.

Authors:  Joo-Pin Foo; Konstantinos N Aronis; John P Chamberland; Jason Paruthi; Hyun-Seuk Moon; Christos S Mantzoros
Journal:  Diabetes Care       Date:  2012-11-27       Impact factor: 19.112

View more
  3 in total

1.  Differential Effects of Oral and Intravenous Lipid Administration on Key Molecules Related to Energy Homeostasis.

Authors:  Maria T Vamvini; Ole-Petter Hamnvik; Ayse Sahin-Efe; Anna Gavrieli; Fadime Dincer; Olivia M Farr; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2016-03-10       Impact factor: 5.958

2.  FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure.

Authors:  Salah Sommakia; Naredos H Almaw; Sandra H Lee; Dinesh K A Ramadurai; Iosif Taleb; Christos P Kyriakopoulos; Chris J Stubben; Jing Ling; Robert A Campbell; Rami A Alharethi; William T Caine; Sutip Navankasattusas; Guillaume L Hoareau; Anu E Abraham; James C Fang; Craig H Selzman; Stavros G Drakos; Dipayan Chaudhuri
Journal:  Circ Heart Fail       Date:  2021-12-06       Impact factor: 8.790

Review 3.  Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers.

Authors:  Yue Sui; Jianping Chen
Journal:  Int J Biol Sci       Date:  2022-10-03       Impact factor: 10.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.